Bruno Speder, SGS Life Sciences, gives an overview of new EU regulation 536/2014, introduced to provide a single European submission and approval procedure for clinical trials, and discusses the effects it may have on early phase clinical trials
A recent partnership to address the challenge of monitoring adherence in ophthalmic clinical trials was formed between Aptar Pharma and Kali Care. Here, Sina Fateh and Sai Shankar discuss this alliance further.
In this article, Ben van der Schaaf, principal at Arthur D. Little, gives a five-step guide to explore possible funding partnerships for lower-priority drug trials — a new model for big pharma.
Speed to market is a significant concern in tablet manufacturing, however, moving too quickly may cause problems. Here, Dr Charles Kettler and Robert Sedlock reveal anticipatory experiments to help make the transition from R&D to full scale smooth.
Dr Rajendra Wable, subject matter expert-medical writing and regulatory affairs at Sciformix Corporation, discusses how marketing authorisation applications across Europe, Australia and other countries can be supported with non-clinical overviews
A recent study from Zebra Technologies has revealed that manufacturers are investing in wearable technologies to eliminate pen and paper from supply chains
Dr Prashanth BSB, head of safety and medical writing for ELC Group, talks to EPM about the ramifications Brexit may have on the pharmacovigilance landscape.
As pharma anticipates the forthcoming Brexit negotiations and future uncertainty, Stephie Castling, senior marketing executive from Denny Bros, examines the regulatory concerns coming to the fore in the industry.
CPhI Worldwide, organised by UBM, have announced the panel for the 2017 Annual Industry Report, which will represent the fifth edition. As such, a decision has been made to review the past five years’ reports to see how accurate the predictions were.
Dr Marisa Miraldo, associate professor in Health Economics at Imperial College Business School, London, discusses ways to accelerate innovation in healthcare for the benefit of patients, healthcare providers and industry.
Focusing on the keys to success for contract drug manufacturers, Arnaud Sergent, Serge Hovsepian, Nohmie Ben Rekassa and Ben Faircloth from L.E.K. Consulting detail the differentiation strategies that have proven themselves in the marketplace
